Humana Inc vs Rivian Automotive, Inc. — how do they compare? Humana Inc trades at $451.05 (market cap $46.49B), while Rivian Automotive, Inc. trades at $14.2 (market cap $20.75B). The key difference: Humana Inc is far larger — about 2.2× Rivian Automotive, Inc.'s market cap, and Humana Inc pays a 0.91% dividend while Rivian Automotive, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Humana Inc for 53 Days and Rivian Automotive, Inc. for 61 Days on average.
| HUM | RIVN | |
|---|---|---|
Market Cap | $46.49B | $20.75B |
Volume | 2,567,704 | 26,144,654 |
Sector | Health | Consumer Cyclical |
52-Week High | $409.85 | $22.45 |
52-Week Low | $163.67 | $12.50 |
Typical Hold Time | 53 Days | 61 Days |
Enterprise Value | $53.84B | $20.79B |
Dividend Yield | 0.91% | — |
Signals from Pluang's Aura AI — not financial advice
Humana (HUM) trades at $396.51, down 1.92% on the day, with strong technical momentum showing bullish moving averages and key support at $391. The company demonstrates consistent revenue growth reaching $129.7B in 2025, though net margins have compressed to 0.88%. Recent quarterly earnings have exceeded expectations, with Q2 2026 EPS of $7.61 beating estimates of $7.27. Analyst sentiment remains positive with a $432.63 consensus price target representing 9% upside potential from current levels.
The investment case centers on Humana's dominant Medicare Advantage position and consistent revenue growth, though margin pressure and regulatory scrutiny present headwinds. With 43% of analysts maintaining buy ratings and institutional accumulation continuing, the stock offers exposure to healthcare demographics but requires monitoring of enrollment trends and cost management execution.
Rivian Automotive (RIVN) trades at $14.34, down 1.17% amid bearish technical signals despite strong Q3 2026 delivery growth of 46% to 19,248 vehicles. The company maintains negative profitability with a -54.95% net income margin but shows improving cash flow trends with operating losses narrowing from -$5.1B in 2022 to -$779M in 2025. Recent news highlights R2 SUV production ramp and autonomy technology development, though the stock faces pressure from unchanged 2026 guidance and a recent R2 battery pack recall.
Rivian presents a high-risk growth opportunity with significant cash burn but improving operational efficiency. The path to profitability depends on successful R2 scaling and future autonomy revenue, while near-term risks include execution challenges and competitive EV market pressures. Analyst consensus remains cautiously optimistic with a $16.89 price target representing 18% upside potential.
Trailing returns across standard periods
Latest headlines on both assets
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →Rivian Automotive, Inc. is an automotive technology company. The Company designs and manufactures vans, trucks, and sports utility vehicles, as well as offers repair and maintenance services. Rivian Automotive serves customers in North America and the United Kingdom.
Read more on RIVN →